Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma

Annemiek Broijl*, Marie-Jose Kersten, Wendimagegn Ghidey Alemayehu, Mark-David Levin, Okke de Weerdt, Edo Vellenga, Ellen Meijer, Shulamit Wittebol, Bea C. Tanis, Petra B. Cornelisse, Marian Stevens-Kroef, Gerard M. J. Bos, Pierre W. Wijermans, Henk Lokhorst, Pieter Sonneveld

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article numbere149
JournalHaematologica-the Hematology Journal
Volume101
Issue number4
DOIs
Publication statusPublished - Apr 2016

Keywords

  • escalated dose
  • VRD
  • first relapse
  • multiple myeloma

Cite this